Annexon, Inc. (ANNX) News
Follow Annexon, Inc. (ANNX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 17 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Atrium Therapeutics Q3 Collaboration Revenue Rises on BMS Milestone
EQUITY | Nov 12, 2026, 09:18 PM UTC
M
Annexon Biosciences Q3 Loss Narrows as Cash Runway Extends to 2028
Annexon Biosciences reported a narrower third-quarter net loss, citing lower research and development expenses, and said its cash runway extends to 2028.
EQUITY | Nov 09, 2026, 09:21 PM UTC
L
Form SCHEDULE 13G/A Annexon, Inc. Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:12 PM UTC
L
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision OutcomesARCHER II is the First Pivotal Trial Designed to Demons
NEWS | Sep 24, 2026, 12:03 PM UTC
L
ANNX - Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
ANNX - Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
NEWS | Sep 24, 2026, 12:01 PM UTC
M
Annexin treats first NEXUS expanded-cohort patient in Germany
Annexin Pharmaceuticals treated the first NEXUS expanded-cohort patient in Germany with anti-VEGF followed by vanexin. The patient completed Day 15 follow-up with no adverse events.
EQUITY | Sep 17, 2026, 06:31 AM UTC
L
ANNX - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
ANNX - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 16, 2026, 08:05 PM UTC
L
Annexin Pharmaceuticals to Present at Investing in Life Science on September 22
The 4th edition of Investing in Life Science takes place on September 22 in Stockholm. Anders Haegerstrand, CEO will present Annexin Pharmaceuticals to specialist life science investors and potential strategic partners.I
EQUITY | Sep 10, 2026, 07:01 AM UTC
L
ANNX: Phase III programs in GBS and GA advance toward key data and regulatory milestones, with strong differentiation
Late-stage programs in GBS and GA are advancing, with strong clinical data and regulatory filings in progress. The GA study's unique focus on functional vision and mechanistic differentiation positions it for significant
EQUITY | Sep 09, 2026, 02:30 PM UTC
L
ANNX late-stage GBS and GA programs advancing; US, Europe filings due soon
Late-stage programs in GBS and GA are advancing, with clinical efficacy and trial design described as robust. Regulatory filings in the US and Europe are expected soon, per TradingView News.
EQUITY | Sep 09, 2026, 01:51 PM UTC
L
Annexon to participate in September investor conferences
Annexon, Inc. said Douglas Love, Esq. will participate in upcoming September investor conferences.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
ANNX - Annexon to Participate in Upcoming September Investor Conferences
ANNX - Annexon to Participate in Upcoming September Investor Conferences
EQUITY | Sep 02, 2026, 12:01 PM UTC
L
JPM maintains Annexon overweight and raises price target to $14
JP Morgan maintains Annexon at overweight and raises its price target to $14.00 per share from $10.00.
EQUITY | Sep 01, 2026, 06:44 PM UTC
L
Annexon (ANNX) reports inducement grants under Nasdaq Rule 5635(c)(4)
Annexon (ANNX) reports inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4).
REGULATION | Aug 17, 2026, 08:05 PM UTC
L
ANNX Reports Q2 2026 Financial Results
ANNX reports second quarter 2026 financial results and business updates
EARNINGS | Aug 12, 2026, 10:05 AM UTC
M
ANNX Expands Vonaprument Phase 3 Program
ANNX expands Vonaprument Phase 3 program in geographic atrophy
EQUITY | Aug 12, 2026, 10:00 AM UTC
H
Annexon Reports Positive Clinical Responses
Annexon's GBS FORWARD study shows positive responses
EQUITY | Aug 06, 2026, 12:00 PM UTC
H
Annexon secures $200M credit facility
Annexon gets $200M credit facility
EQUITY | Jul 30, 2026, 08:02 PM UTC
L
ANNX Initiated Underperform and $3 PT @ Citizens
ANNX Initiated Underperform and $3 PT @ Citizens
EQUITY | Jul 21, 2026, 12:04 PM UTC
L
ANNX PT raised from $11 to $25, maintains Buy @ Needham
ANNX PT raised from $11 to $25, maintains Buy @ Needham
EQUITY | Jul 15, 2026, 12:33 PM UTC
L
ANNX Annexon Inc. - Annexon to Present Phase 2 Archer Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Let
ANNX Annexon Inc. - Annexon to Present Phase 2 Archer Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
EQUITY | Jul 14, 2026, 08:14 PM UTC